NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

334.50 -0.55 (-0.16%)

835.6K NSE+BSE Volume

NSE 28 May, 2025 1:35 PM (IST)

40,160.1

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

14 Jul 2017

334.50

-0.16%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

In a significant development that can be termed as a precursor for biosimilar launch in the US, the USFDA Oncologic Drugs Advisory Committee (ODAC) has strongly recommended approval of Biocon/Mylan's proposed biosimilar Trastuzumab, a biologically similar version of Roche's breast-cancer drug Herceptin. Herceptin is indicated to treat certain HER2-positive breast and gastric cancers. The committee voted 16-0 in support of eligible indications of the reference product. During the discussion, ODAC determined that no clinically meaningful...

Biocon Ltd. is trading below its 100 day SMA of 346.1

Biocon Ltd.

20 May 2017

334.50

-0.16%

Biocon Ltd Q4FY17 results comment

Results Update: Biocon Ltd.

HDFC Securities

Revenue fell by 10.1% to Rs. 919.2 Cr in Q4FY17 when compared to the previous quarter. Also it decreased by 1.53% when compared with Q4FY16.

Biocon Ltd.'s price crossed above 50Day SMA today

Biocon Ltd.

02 May 2017

334.50

-0.16%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 1.5% YoY to | 931 crore (I-direct estimate: | 1055 crore) due to elongated approval timelines in emerging markets, discontinuance of in-licensed products and fire incident at Syngene EBITDA margins contracted 70 bps YoY to 20.1% (I-direct estimate: 25%) mainly due to higher raw material & employee cost. EBITDA declined 4.8% YoY to | 188 crore (I-direct estimate: | 264 crore) Net profit increased 106% YoY to | 127.5 crore (I-direct estimate:...

Biocon Ltd. is trading above its 50 day SMA of 332.6

Biocon Ltd.

02 Feb 2017

334.50

-0.16%

Result Update:Biocon

Hold: Biocon Ltd.

Axis Direct

Q3FY17 PAT (up 67% YoY) was 21% higher than our estimate due to 2.5x increase in licensing income (directly flows to PBT). While EBITDA margin improved to 25.7% (up 401 bps YoY), margin (ex-licensing) improved slightly (up 93 bps YoY) to 19.5%. Much-awaited Insulin facility in Malaysia is commercial..

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

31 Jan 2017

334.50

-0.16%

Biocon Ltd Q3FY17 results comment

Results Update: Biocon Ltd.

HDFC Securities

Revenue grew by 9.7% to Rs. 1022.5 Cr in Q3FY17 when compared to the previous quarter. Also, it grew by 29.59% when compared with Q3FY16.

Biocon Ltd. is trading below its 100 day SMA of 346.1

Biocon Ltd.

27 Jan 2017, 12:00AM

334.50

-0.16%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 29% YoY to | 1044 crore (I-direct estimate: | 996 crore) mainly due to a sharp jump in licensing income and robust growth in biologics. Licensing income increased to | 79 crore from | 32 crore in Q3FY16. Biologics revenues grew 60% to | 120 crore EBITDA margins improved 354 bps YoY to 26.4% (I-direct estimate: 24.2%) mainly due to lower raw material & other expenses. Higher licensing income was also contributed to EBITDA...

Biocon Ltd.'s price crossed above 50Day SMA today

Biocon Ltd.

24 Oct 2016

334.50

-0.16%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 19.8% YoY to | 954 crore (I-direct estimate: | 1043 crore) mainly due to higher licensing income & growth in biological business. Biological segment revenues grew 26.3% YoY to | 96 crore (I-direct estimate: | 120 crore) EBITDA margins improved 392 bps YoY to 25.2% (I-direct estimate: 23.9%) due to higher licensing income and lower R&D; expenses...

Biocon Ltd.'s price crossed above 50Day SMA today

Is Biocon Ltd. worth buying?

716 Votes:

Buy 75.14%

Sell 16.34%

Hold 8.52%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf